HRP20180718T1 - Oligopeptidni spojevi i njihova upotreba - Google Patents

Oligopeptidni spojevi i njihova upotreba

Info

Publication number
HRP20180718T1
HRP20180718T1 HRP20180718TT HRP20180718T HRP20180718T1 HR P20180718 T1 HRP20180718 T1 HR P20180718T1 HR P20180718T T HRP20180718T T HR P20180718TT HR P20180718 T HRP20180718 T HR P20180718T HR P20180718 T1 HRP20180718 T1 HR P20180718T1
Authority
HR
Croatia
Prior art keywords
oligopeptidic compounds
oligopeptidic
compounds
Prior art date
Application number
HRP20180718TT
Other languages
English (en)
Inventor
Marit Otterlei
Per Arne Aas
Ermadoldin Feyzi
Original Assignee
Apim Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apim Therapeutics As filed Critical Apim Therapeutics As
Publication of HRP20180718T1 publication Critical patent/HRP20180718T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03044—Xenobiotic-transporting ATPase (3.6.3.44)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
HRP20180718TT 2008-02-22 2018-05-09 Oligopeptidni spojevi i njihova upotreba HRP20180718T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0803352.4A GB0803352D0 (en) 2008-02-22 2008-02-22 Oligopeptidic compounds and uses thereof
US10058408P 2008-09-26 2008-09-26
PCT/GB2009/000489 WO2009104001A2 (en) 2008-02-22 2009-02-20 Oligopeptidic compounds and uses thereof
EP09713402.7A EP2254904B1 (en) 2008-02-22 2009-02-20 Oligopeptidic compounds and uses thereof

Publications (1)

Publication Number Publication Date
HRP20180718T1 true HRP20180718T1 (hr) 2018-07-13

Family

ID=39284467

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20220585TT HRP20220585T3 (hr) 2008-02-22 2009-02-20 Oligopeptidni spojevi i njihove uporabe
HRP20180718TT HRP20180718T1 (hr) 2008-02-22 2018-05-09 Oligopeptidni spojevi i njihova upotreba
HRP20220585 HRP20220585T1 (hr) 2008-02-22 2022-05-05

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20220585TT HRP20220585T3 (hr) 2008-02-22 2009-02-20 Oligopeptidni spojevi i njihove uporabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20220585 HRP20220585T1 (hr) 2008-02-22 2022-05-05

Country Status (23)

Country Link
US (3) US8871724B2 (hr)
EP (2) EP3338790B1 (hr)
JP (2) JP5863240B2 (hr)
KR (3) KR101653774B1 (hr)
CN (1) CN102015758B (hr)
AU (1) AU2009216567B2 (hr)
BR (1) BRPI0908853B1 (hr)
CA (1) CA2715940C (hr)
DK (2) DK3338790T3 (hr)
ES (2) ES2912122T3 (hr)
GB (1) GB0803352D0 (hr)
HR (3) HRP20220585T3 (hr)
HU (2) HUE059174T2 (hr)
IL (1) IL207384B (hr)
LT (2) LT2254904T (hr)
MX (1) MX2010008989A (hr)
NO (1) NO2254904T3 (hr)
PL (2) PL3338790T3 (hr)
PT (2) PT3338790T (hr)
RU (1) RU2549675C2 (hr)
TR (1) TR201807218T4 (hr)
WO (1) WO2009104001A2 (hr)
ZA (2) ZA201005506B (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
GB201001602D0 (en) * 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
US20130059773A1 (en) * 2010-02-24 2013-03-07 Veronique Witko-Sarsat Compounds for the treatment of inflammation and neutropenia
US10106855B2 (en) 2012-11-09 2018-10-23 The Johns Hopkins University Genetic assay to determine prognosis in Polycythemia Vera patients
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
US10526385B2 (en) 2013-10-17 2020-01-07 Bao Kang Biomedical Healthcare Inc YAP protein inhibiting polypeptide and application thereof
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
EP3126378B1 (en) * 2014-04-02 2019-01-02 Marshall University Research Corporation Cardiotonic steroid antagonists and related methods
US10441628B2 (en) 2014-10-17 2019-10-15 Bao Kang Biomedical Healthcare Inc High activity tumour inhibitor and preparation method and use thereof
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
GB201507721D0 (en) * 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Immunosuppressive agents and their use in therapy
JP6995627B2 (ja) * 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2019532915A (ja) 2016-08-05 2019-11-14 イエール ユニバーシティ 小児鎌状赤血球貧血患者における脳卒中予防のための組成物および方法
IL254361A0 (en) * 2017-09-06 2017-11-30 Nat Inst Biotechnology Negev Ltd Compounds to suppress the methyltransferase setd6
GB202006699D0 (en) 2020-05-06 2020-06-17 Therapim Pty Ltd Dosage regimen
KR102483938B1 (ko) * 2020-06-12 2023-01-04 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 항알러지 또는 아토피피부염 개선용 조성물
CN112813042B (zh) * 2021-02-08 2021-08-27 南京市妇幼保健院 乳腺脂肪组织来源的多肽及其抗肿瘤应用
WO2024011300A1 (en) * 2022-07-13 2024-01-18 L'oreal Modified peptides, composition, method for inhibiting contraction of muscle cells, method for improving the skin and use of a modified peptide

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE189231T1 (de) 1989-04-10 2000-02-15 Helix Biomedix Inc Lytische peptide, verwendung als wachstumsfördernde mittel und für infektionen und krebs
CA2070416A1 (en) * 1989-10-23 1991-04-24 Richard Ingram Polypeptide inhibitors of gamma interferon
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
CA2119463C (en) 1991-09-20 2003-09-16 Leu-Fen H. Lin Glial cell line-derived neutrophic factor
US5534110A (en) 1993-07-30 1996-07-09 Lam Research Corporation Shadow clamp
WO1995010297A1 (en) 1993-10-15 1995-04-20 Xoma Corporation Method of treating depressed reticuloendothelial system function
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
ATE374369T1 (de) 1997-03-14 2007-10-15 Crusade Lab Ltd Verfahren zur erkennung von regulatoren des zellzyklus
JP2002505077A (ja) 1997-12-10 2002-02-19 ワシントン大学 抗病原体システムおよびその使用方法
TWI227136B (en) 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
DK1091745T3 (da) 1998-06-29 2008-12-15 Los Angeles Childrens Hospital Behandling af hyperproliferative forstyrrelser
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6127177A (en) 1998-09-11 2000-10-03 Massachusetts Institute Of Technology Controlled reversible poration for preservation of biological materials
JP2002530059A (ja) 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
WO2000075184A1 (en) 1999-06-04 2000-12-14 Yale University Modulation of protein levels using the scf complex
US6696263B1 (en) 1999-09-23 2004-02-24 Rigel Pharmaceuticals, Inc. PCNA associated cell cycle proteins, compositions and methods of use
CN1297923A (zh) * 1999-11-29 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人含细胞色素c结构域的脂蛋白105和编码这种多肽的多核苷酸
GB9928323D0 (en) 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
CA2392398A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001238347A1 (en) 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
JP4503801B2 (ja) * 2000-09-08 2010-07-14 独立行政法人科学技術振興機構 新規ヒト癌・精巣抗原及びその遺伝子
US6627401B2 (en) * 2000-12-28 2003-09-30 Council Of Scientific And Industrial Research Method for detecting a single nucleotide polymorphism in p21waf1/cip1 gene as an indicator of risk of esophageal cancer
US6875744B2 (en) 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
KR100891157B1 (ko) 2001-03-28 2009-04-07 헬릭스 바이오메딕스, 인코포레이티드 짧은 생물활성 펩티드 및 그것들의 사용 방법
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
WO2003042239A1 (en) * 2001-11-12 2003-05-22 Stichting Sanquin Bloedvoorziening Peptides inhibiting signaling by ras-like gtpases
WO2003051312A2 (en) 2001-12-18 2003-06-26 Sloan-Kettering Institute For Cancer Research E2f and cancer therapy
US7517857B2 (en) 2002-01-29 2009-04-14 Posco Immune-modulating peptide
AU2003213700A1 (en) 2002-03-01 2003-09-16 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
CA2496215C (en) * 2002-08-20 2013-07-16 Polyphor Ltd. Template-fixed peptidomimetics with antibacterial activity
AU2003294217A1 (en) * 2002-08-29 2004-05-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
ATE378592T1 (de) * 2002-10-02 2007-11-15 Theraptosis S A Verfahren zum screening für modulatoren von mitochondrialer funktion
FR2849603B1 (fr) 2003-01-07 2006-09-08 Centre Nat Rech Scient Composition pour le transport intracellulaire de macromolecules ou particules biologiques
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
FR2855178B1 (fr) 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
US7772367B2 (en) * 2004-01-30 2010-08-10 The Trustees Of Columbia University In The City Of New York C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
ES2400567T3 (es) * 2004-04-21 2013-04-10 The University Of Chicago Inhibidores de cinasa de la cadena ligera de miosina y su uso
GB0410498D0 (en) 2004-05-11 2004-06-16 Cyclacel Ltd Crystal
WO2006005042A2 (en) * 2004-06-30 2006-01-12 Cemines, Inc. Methods and compositions for the diagnosis,prognosis,and treatment of cancer
BRPI0519737A2 (pt) * 2004-12-21 2009-01-27 Musc Found For Res Dev composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos
IN2005CH00851A (hr) * 2005-07-04 2008-01-25
WO2007019532A2 (en) 2005-08-04 2007-02-15 North Carolina State University Peptide aptamers that bind to the rep proteins of ssdna viruses
EP1942115A4 (en) * 2005-10-26 2009-03-18 Chugai Pharmaceutical Co Ltd AGGLUTINABLE GLP-1 ANALOGUE AND PROLONGED RELEASE PHARMACEUTICAL COMPOSITION
CA2638866C (en) 2006-02-17 2015-11-10 Indiana University Research And Technology Corporation Peptide based inhibition of capcna protein-protein interactions in cancer
CU23511B6 (es) 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
JP5590882B2 (ja) 2006-06-26 2014-09-17 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 化学療法増感剤としてのシステインに富む酸性分泌タンパク質（ｓｐａｒｃ）
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof

Also Published As

Publication number Publication date
JP2011512150A (ja) 2011-04-21
US20170246248A1 (en) 2017-08-31
EP3338790B1 (en) 2022-04-13
KR101653774B1 (ko) 2016-09-05
CA2715940C (en) 2020-06-30
US8871724B2 (en) 2014-10-28
US9676822B2 (en) 2017-06-13
KR20160038903A (ko) 2016-04-07
EP2254904B1 (en) 2018-04-11
LT2254904T (lt) 2018-06-11
LT3338790T (lt) 2022-05-25
ES2912122T3 (es) 2022-05-24
MX2010008989A (es) 2010-12-07
KR20170018485A (ko) 2017-02-17
TR201807218T4 (tr) 2018-06-21
PT2254904T (pt) 2018-06-04
ZA201005506B (en) 2011-10-26
DK2254904T3 (en) 2018-06-06
RU2549675C2 (ru) 2015-04-27
WO2009104001A2 (en) 2009-08-27
PL2254904T3 (pl) 2018-08-31
ES2670334T3 (es) 2018-05-30
US20150017232A1 (en) 2015-01-15
HRP20220585T1 (hr) 2022-08-19
CN102015758A (zh) 2011-04-13
US10213483B2 (en) 2019-02-26
KR20100123728A (ko) 2010-11-24
EP3338790A2 (en) 2018-06-27
JP2015180634A (ja) 2015-10-15
EP3338790A3 (en) 2018-07-11
HRP20220585T3 (hr) 2022-08-19
HUE059174T2 (hu) 2022-10-28
ZA201105685B (en) 2012-05-25
EP2254904A2 (en) 2010-12-01
PL3338790T3 (pl) 2022-07-11
NO2254904T3 (hr) 2018-09-08
DK3338790T3 (da) 2022-05-09
US20110020437A1 (en) 2011-01-27
GB0803352D0 (en) 2008-04-02
AU2009216567A1 (en) 2009-08-27
WO2009104001A3 (en) 2010-04-15
PT3338790T (pt) 2022-05-11
CA2715940A1 (en) 2009-08-27
BRPI0908853A2 (pt) 2017-05-30
BRPI0908853B1 (pt) 2021-05-25
IL207384B (en) 2018-05-31
JP5863240B2 (ja) 2016-02-16
KR101749204B1 (ko) 2017-06-20
HUE037737T2 (hu) 2018-09-28
CN102015758B (zh) 2017-04-12
RU2010134786A (ru) 2012-03-27
IL207384A0 (en) 2010-12-30
KR101758671B1 (ko) 2017-07-17
AU2009216567B2 (en) 2013-11-07
JP6116614B2 (ja) 2017-04-19

Similar Documents

Publication Publication Date Title
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
IL254218A0 (en) Pipedrine-bridged compounds of the quinoxaline-converted type and their use
HK1196358A1 (en) Substituted pyridin-2-ones and pyridazin-3-ones -2--3-
IL210804A (en) Benzylidenehydrazides and their uses
PT2114900T (pt) Compostos à base de tiopirimidina e as suas utilizações
LT3222617T (lt) Psma nukreipti junginiai ir jų naudojimas
GB0818241D0 (en) Compounds and their use
IL208081A0 (en) Amido - thiophene compounds and their use
ZA201007395B (en) Aryl-quinolyl compounds and their use
PL2344449T3 (pl) Związki arylo-fenylo-sulfonamido-cykloalkilowe i ich zastosowanie
ZA201103456B (en) Leukolectins and uses thereof
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
PL2247601T3 (pl) Tiazopirymidynony i ich zastosowanie
TWI367210B (en) Estrogenic-active compounds and application thereof
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0801319D0 (en) Compounds and their use
GB0708445D0 (en) Compounds and uses thereof
IL200459A0 (en) Alpha-halo-and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof
GB0813254D0 (en) Compounds and their use
GB0817897D0 (en) Compounds and their use
GB0802194D0 (en) Compounds and their use
GB0808857D0 (en) Methdos and uses